TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Study Comparing the Efficacy of Two Ibuprofen Formulations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria :~* Outpatients with post-operative pain following surgical extraction of third molars,~* examined by the attending dentist or physician and medically cleared to participate in the study,~* in general good health and have no contraindications to the study or rescue medication.~Exclusions criteria:~* any serious medical condition,~* acute localized dental infection at the time of surgery ,~* females who are pregnant, lactating, of child-bearing potential, or post-menopausal for less than 2 years and not using a medically approved method of contraception.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): None
- 3 (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Participants With Alzheimer's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~Diagnosis of probable Alzheimer's disease (AD).~The participant has clinically significant symptoms of agitation secondary to AD, that interfere with daily routine and for which a prescription medication is deemed indicated, in the opinion of the investigator.~Either out-patients or residents of an assisted-living facility or a skilled nursing home.~CGI-S score is ≥ 4 (moderately ill) at screening and baseline.~Mini Mental State Examination (MMSE) score at screening between 8 and 28 (inclusive).~Caregiver who is able and willing to comply with all required study procedures, ensuring that the participant attends all study visits and takes the study medication as instructed. In order to qualify as a caregiver for this study, the individual should spend time with the participant for a minimum of 4 hours on 4 separate days per week.~Key Exclusion Criteria:~Participant has other type of dementia (e.g., vascular dementia, frontotemporal dementia, Parkinson's disease, substance-induced dementia).~Participant with co-existent clinically significant or unstable systemic diseases that could confound the interpretation of the safety results of the study (e.g. malignancy, poorly controlled diabetes, poorly controlled hypertension, unstable pulmonary, renal or hepatic disease, unstable ischemic cardiac disease, dilated cardiomyopathy, certain cardiac conduction abnormalities including QTc prolongation, or unstable valvular heart disease).~Participant with myasthenia gravis.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants will receive placebo during Stage 1 and Stage 2 of the study.
- AVP-923 (Type: EXPERIMENTAL): Participants will receive AVP-923-20 and AVP-923-30 in a sequential manner during Stage 1 and Stage 2 of the study.
- Placebo then AVP-923 (Type: EXPERIMENTAL): Participants will receive placebo in Stage 1 followed by AVP-923 in Stage 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Weight Loss for Prediabetes Using Episodic Future Thinking

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Overweight or obese (BMI ≥ 25)~* Prediabetes (HbA1c between 5.7 - 6.4%; 39-40 mmol/mol)~Exclusion Criteria:~* Type 2 Diabetes~* Use of diabetic drugs~* Pregnancy~* Not ambulatory~* Intellectual impairment~* Unmanaged mood disorders~* Current substance use disorder (excluding nicotine and caffeine)~* History of eating disorders (Except binge eating disorder)~* Abnormal blood glucose related to medications

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Episodic Future Thinking (EFT) (Type: EXPERIMENTAL): Participants will generate positive future cues that will be accessed via an electronic app to engage in EFT.
- Daily Check in (DCI) (Type: PLACEBO_COMPARATOR): Participants will be asked to access an electronic app daily, but will receive no cues.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical 0.4% Ketorolac and Vitreoretinal Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age of 18, routine elective vitrectomy~Exclusion Criteria:~* history of trauma, uveitis, prior intraocular surgery within 3 months, requirement of mechanical pupil dilation, prior inclusion of other eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- A (Type: PLACEBO_COMPARATOR): None
- B (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Efficacy of Two Combination Regimens for the Neisseria Gonorrhoeae and Chlamydia Coinfection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient over 18 ages with laboratory-documented uncomplicated Chlamydia trachomatis and Neisseria gonorrhoeae reinfection at any site~Exclusion Criteria:~* Pregnancy~* Breast feeding~* Hypersensitivity to cephalosporins or penicillins~* significant renal failure or hepatic failure

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Doxycycline plus ceftriaxone (Type: EXPERIMENTAL): Each subject will receive 100 mg doxycycline twice daily for seven days and a single dose of ceftriaxone 1000 mg intravenously
- Doxycycline plus cefixime (Type: ACTIVE_COMPARATOR): Each subject will receive 100 mg doxycycline twice daily for seven days and a single oral dose of cefixime 800 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Does Treximet Improve Productivity and Patient Satisfaction Due to Sustained Response and Consistency of Response?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* episodic migraine diagnosis~* age 18 or older~* currently using a triptan as primary migraine monotherapy~* currently employed~* if of childbearing potential, willing to prevent pregnancy during study participation~* able to understand and consent to study participation~Exclusion Criteria:~* younger than age 18~* not having episodic migraine diagnosis~* not using a triptan as primary migraine monotherapy~* not currently employed~* pregnant or nursing or unwilling to prevent pregnancy during study participation~* unable to understand and consent to study participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Triptan (Type: ACTIVE_COMPARATOR): Arm 1 subjects began with their prescribed triptan
- Treximet 85Mg-500Mg Tablet (Type: ACTIVE_COMPARATOR): Arm 2 subjects began with Treximet (sumatriptan 85 mg/naproxen sodium 500 mg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Oxaliplatin, Capecitabine, and Radiation Therapy in Treating Patients With Locally Advanced Cancer of the Rectum

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed adenocarcinoma of the rectum~  * Tumor involving the distal 12 cm of the rectum (above the anal verge)~ * Clinically staged by endoscopic ultrasound with one of the following criteria:~    * T3-T4 disease~   * Evidence of lymph node involvement, defined by the presence of ≥ 1 enlarged peri-rectal lymph node (≥ 1 cm in size)~* No known distant metastases~PATIENT CHARACTERISTICS:~Age~* 18 to 75~Performance status~* ECOG 0-1 OR~* Karnofsky 70-100%~Life expectancy~* More than 1 year~Hematopoietic~* WBC ≥ 3,000/mm\^3~* Absolute neutrophil count ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~Hepatic~* Bilirubin normal~* AST and ALT ≤ 2.5 times upper limit of normal~Renal~* Creatinine normal OR~* Creatinine clearance ≥ 60 mL/min~Cardiovascular~* No symptomatic congestive heart failure~* No unstable angina pectoris~* No cardiac arrhythmia~Other~* Able to receive oral medication~* No other malignancy within the past 5 years except nonmelanoma skin cancer~* No prior or concurrent significant neuropathy~* No prior allergic reaction attributed to compounds of similar chemical or biological composition to study drugs~* No ongoing or active infection~* No other concurrent uncontrolled illness~* No psychiatric illness or social situation that would preclude study compliance~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective double-method contraception during and for 3 months after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No concurrent granulocyte-stimulating factors~Chemotherapy~* No prior chemotherapy~Endocrine therapy~* Not specified~Radiotherapy~* No prior pelvic radiotherapy~Surgery~* Not specified~Other~* No other concurrent investigational agents~* No other concurrent anticancer agents or therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ketofol for Preventing Postoperative Delirium in Elderly Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patient acceptance.~* Age ≥ 60 years old.~* American society of anesthesia (ASA) (II-III).~* Gender: males \&females~* BMI \< 35kg/m2.~* able to communicate verbally.~* Scheduled for exploration surgery for intestinal obstruction under general anesthesia of at least 60 min duration~Exclusion Criteria:~* Patient refusal.~* Patients with delirium prior to surgery.~* Patients with drug misuse history or taking anti-psychotic drugs.~* Previous hospitalization within 3 months.~* Legal blindness, severe deafness.~* History of Acute cerebrovascular conditions; stroke or transient ischemic attack.~* Patients who could not be prepared with proper fluid resuscitation, electrolyte and acid-base correction prior to surgery.~* Patients who could be discharged from the intensive care unit (ICU) within two days.~* Patients with a known history of allergy to study drugs

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): 21 ml of normal saline 0.9% will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively.
- ketofol group (Type: ACTIVE_COMPARATOR): 21 ml of a mixture of (ketamine and propofol) will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively
- dexmedetomidine group (Type: ACTIVE_COMPARATOR): 21 ml of a mixture of (dexmedetomidine diluted with normal saline 0.9%) will be I.V continuously infused fifteen minutes after induction of anesthesia up to two hours postoperatively

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Expiratory Muscle Training for Persons With Neurodegenerative Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Multiple Sclerosis Participants~* Diagnosis of primary, secondary, or relapsing-remitting MS by a neurologist~* Over 85% of the patient populations that come from the study sites demonstrate relapsing-remitting MS with an average relapse frequency of once every 3 years~Parkinson's Disease Participants~* Hoehn \& Yahr, stage II and III as indicated by certified movement disorders neurologist~All Participants~* Between 35 and 80 years of age~* Non-smoking or no smoking within the previous five years~* No history of head and neck cancer, asthma or COPD, untreated hypertension~* Sufficient facial muscle strength so as to achieve and maintain adequate lip closure around a circular mouthpiece~* Cognition within normal limits as determined by the: Mini Mental Status Exam (MMSE; 1975No neurological (other than MS or PD) condition which adversely affects respiratory muscle or gas exchange system~* Reduced MEP's compared to published normative data for age and sex~* Reduced expiratory peak flow rates (6-8 L/s for young to middle age adults and 3.6 L/s for 65 and older) during voluntary cough production for age and sex (Bolser, personal communication; Smith-Hammond \& Goldstein, 2006)~* Participant report of symptoms related to swallow impairment~Exclusion Criteria:~* DBS~* COPD~* Asthma~* Smoking or smoking within preceding 5 years

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1: EMST (Type: ACTIVE_COMPARATOR): The experimental group receives five weeks of expiratory muscle strength training (EMST) using a positive pressure threshold device
- Arm 2: Sham group (Type: SHAM_COMPARATOR): The Sham group undergoes the same 5-week EMST exercise as the experimental group using the same device but without a spring for minimal pressure load

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 19~* Patients who understood the contents and purpose of this trial and signed informed consent form~* Patients with essential hypertension and dyslipidemia~Exclusion Criteria:~* Patients with differences between arms greater than 20 mmHg for mean sitSBP or 10 mmHg for mean sitDBP~* Patients with mean sitSBP ≥ 180 mmHg or mean sitDBP ≥ 110 mmHg~* Concomitant administration of cyclosporine~* Tolerance or Hypersensitivity Angiotensin II receptor blocker or HMG-CoA reductase inhibitor, Calcium channel blocker(dihydropyridine) or Multi-drug allergy~* Hereditary angioedema or medical history of angioedema in the treatment of ACE inhibitors or angiotensin II receptor blockers~* Fibromyalgia, myopathy, rhabdomyolysis or acute myopathy or medical history of adverse effect to statin~* CPK normal range \> 2 times~* Secondary hypertension and suspected secondary hypertension~* Orthostatic hypotension with symptoms~* Uncontrolled primary hypothyroidism(TSH normal range ≥ 1.5 times)~* Severe hepatopathy or active hepatopathy (AST or ALT normal range ≥ 3 times)~* Active gout or hyperuricemia(uric acid ≥ 9mg/dL)~* IDDM or uncontrolled type 2 diabetes mellitus (HbA1c \> 9%)~* Ventricular arrhythmia~* Medical history~  * Severe heart disease(heart failure of NYHA class III-IV)~ * Severe cerebrovascular disease within 6 months (cerebral infarction, cerebral hemorrhage), hypertensive encephalopathy, transient cerebral ischemic attack(TIA)~ * Hypertrophic obstructive cardiomyopathy, severe obstructive coronary artery disease, aortic stenosis, hemodynamically significant stenosis in aortic valve or mitral valve~ * Ischemic heart disease(myocardial infarction, angina) within 6months~ * Angioplasty or coronary artery bypass graft(CABG) surgery within 6months

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): HCP1701
- Active Comparator 1 (Type: ACTIVE_COMPARATOR): HGP0904, HGP0608
- Active Comparator 2 (Type: ACTIVE_COMPARATOR): HGP0608, HCP1306

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Two Versus Three Pneumococcal Conjugate Vaccinations

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Newborn infants eligible for participation in the national infant vaccination program in the Netherlands~Exclusion Criteria:~exclusion from the national vaccination program because of the presence of~* a medical condition requiring treatment that can interfere with the effect of vaccinations~* known or suspected allergy to components of the pneumococcal conjugate vaccine~* known or suspected immunodeficiency disease~* previous treatment with plasma or immunoglobulins~* previous vaccinations other than hepatitis B vaccinations~* coagulation disorders

- Gender: ALL
- Minimum Age: 2 Months
- Maximum Age: 3 Months
- Healthy Volunteers: t

Study Arms:
- 2-dose (Type: EXPERIMENTAL): PCV7 at age 2 and 4 months
- 2+1-dose (Type: EXPERIMENTAL): PCV7 at age 2, 4 and 11 months
- Control (Type: NO_INTERVENTION): Control group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Anidulafungin Plus Voriconazole Versus Voriconazole For The Treatment Of Invasive Aspergillosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Immunocompromised state due to either 1. receipt of hematopoeitic stem cell transplantation or 2. hematologic malignancy;~* Diagnosis of possible, probable, or proven invasive aspergillosis.~Exclusion Criteria:~* Patients with aspergilloma or chronic aspergillosis~* Receipt of 4 or more days of systemic antifungal treatment for the current episode of invasive aspergillosis~* Anticipated survival of less than 5 days or Karnofsky score \<=20

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Voriconazole (Type: ACTIVE_COMPARATOR): Voriconazole monotherapy
- Voriconazole and Anidulafungin (Type: EXPERIMENTAL): Combination therapy with voriconazole and anidulafungin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo and a Currently Available Treatment in Participants With Moderate-to-Severe Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com~Inclusion Criteria:~* Plaque psoriasis for at least 6 months~* Moderate to severe disease~* Candidate for phototherapy or systemic therapy~Exclusion Criteria:~* Other forms of psoriasis~* History of recent infection~* Prior exposure to BMS-986165 or active comparator~Other protocol defined inclusion/exclusion criteria could apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- BMS-986165 (Type: EXPERIMENTAL): BMS-986165 oral administration
- Placebo (Type: PLACEBO_COMPARATOR): Placebo oral administration
- Active comparator (Type: ACTIVE_COMPARATOR): Active comparator oral administration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluate the Safety and Efficacy of Botulax® as Compared to Botox® in Subject With Moderate to Severe Crow's Feet Lines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female of at least 19 to 65 years old~* Bilaterally symmetrical moderator-to-severe CFL at maximum smile on the FWS as rated by the investigator~Exclusion Criteria:~* Subject with hypersensitivity to the investigational products or their components~* Female subject who are pregnant or lactating~* Subject who are unable to communicate or follow the instructions~* Subject who are not eligible for this study based on the judgment of an investigator

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Botulax (Type: EXPERIMENTAL): Single dose
- Botox (Type: ACTIVE_COMPARATOR): Single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete